Farag Kameel D. has filed 6 insider transactions across 2 companies since October 2025.
Most recent transaction: a grant/award of 57500 shares of BIOVIE INC. ($BIVI) on January 05, 2026.
Activity breakdown: 2 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 5, 2026 | BIOVIE INC. | $BIVI | Farag Kameel D. | Director | A | Stock Option (right to buy) | 57500 | $0.00 | 57,500.0000 | 7,920,795 | 9999.99% | 0.73% |
| Dec. 16, 2025 | Akari Therapeutics Plc | $AKTX | Farag Kameel D. | Interim CFO | P | Warrants to purchase American Depositary Shares ("ADRs") | 24745 | $0.00 | 24,745.0000 | 71,479,461,523 | 9999.99% | 0.00% |
| Dec. 16, 2025 | Akari Therapeutics Plc | $AKTX | Farag Kameel D. | Interim CFO | P | Pre-Funded Warrants to purchase ADRs | 24745 | $0.40 | 24,745.0000 | 71,479,461,523 | 9999.99% | 0.00% |
| Nov. 1, 2025 | Akari Therapeutics Plc | $AKTX | Farag Kameel D. | Interim CFO | A | American Depositary Shares representing Ordinary Shares | 32000 | $0.75 | 32,000.0000 | 57,752,981,523 | 9999.99% | 0.00% |
| Nov. 1, 2025 | Akari Therapeutics Plc | $AKTX | Farag Kameel D. | Interim CFO | A | American Depositary Shares representing Ordinary Shares | 26619 | $0.75 | 26,619.0000 | 57,752,981,523 | 9999.99% | 0.00% |
| Oct. 22, 2025 | Akari Therapeutics Plc | $AKTX | Farag Kameel D. | Interim CFO | A | American Depositary Shares representing Ordinary Shares | 6277 | $0.74 | 6,277.0000 | 57,752,981,523 | 9999.99% | 0.00% |